Vitamed Galaj I Cichomski Sp. j.

Bydgoszcz 43 trials 8 recruiting

43 Registered trials

8 Currently recruiting

Organisation

Vitamed Galaj I Cichomski Sp. j.

Location

Bydgoszcz, Poland

Identifier

ORG-100043168

Address

Ul. Tadeusza Kosciuszki 35, 85-079, Poland

Departments

#1702: NZOZ VITAMED
Department
Dermatology
Gastroenterology
N/A
NA
NA/ND
NZOZ VITAMED
Pneumology
Poradnia Kardiologiczna
Poradnia Pulmonologiczna

Clinical trials at this site (43)

Search interface

A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Not authorised

2023-506642-23-00 Active Pulmonary Sarcoidosis 4
A prospective, controlled, randomized, double blind, 2-arms, parallel-group, multicentre, phase 3 study to investigate effectiveness of Acti… Pending

2024-516284-90-00 rhinosinusitis not requiring antibiotic therapy 5
Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros… Pending

2024-518013-25-00 Idiopathic Pulmonary Fibrosis 4
A study to demonstrate the efficacy of PMBL (Ismigen) in the reduction of respiratory infections in children aged 3 to 12 years. Pending

2025-524212-11-00 Respiratory Tract Infections 6
A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Ulcerative Colitis is a type of inflammatory bowel dise 4 2026-01-26
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent Recruiting

2024-518289-28-00 Progressive pulmonary fibrosis [PPF] Idiopathic pulmon 4 2025-07-04
A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis Recruiting

2023-508429-29-00 Progressive Pulmonary Fibrosis 4 2024-09-26
Effect of intravenous ferric carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with r… Recruiting

2024-517206-28-00 Recent myocardial infarction associated with iron defic 6 2022-09-21
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A trial to evaluate efficacy and safety of buloxibutid in people with idiopathic pulmonary fibrosis Ended

2023-509069-19-00 idiopathic pulmonary fibrosis 4 2024-12-12
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Alzheimer's disease 9 2024-06-27
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim… Ended

2023-506183-13-00 Alzheimer’s Disease 4 2024-03-29
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended

2023-504672-22-00 Influenza 5 2023-11-24
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23